There's no shortage of tech podcasts, but few give you a true dose of the future.

The A16Z podcast is an exception.

It takes you straight to the innovators behind new materials, data centers, self-driving cars,

even electric boats, eavesdrop on the future with the A16Z podcast.

HBR presents.

Hello, and welcome to Exponential View, with me, Azim Azar.

The world is changing at an amazing pace and we're entering the exponential age, a fundamental

rewriting of our economic and social order that's catalyzed by some remarkable radical technologies.

Now, on this podcast, I want to bring some clarity to the complexity of this change by helping

you understand the trajectories of these technologies and their implications for business, economics

and daily lives.

In today's discussion, I turn to the multi-decade quest to cure cancer and in particular,

the crucial role in that played by our immune systems.

During the past two years, living under the shadow of the COVID pandemic, popular awareness

of our immune system has grown remarkably. More and sometimes less informed discussions

about cytokine storms, T-cells, B-cells, neutrophils and more have proliferated across social

and traditional media.

Meanwhile, scientific understanding of the immune system has proved commercially valuable.

Eight of the 11 best-selling therapies are immune-centric.

But that commercial potential is more than matched by the complexity of the problems and

immunotherapies remain difficult, expensive and slow to produce.

Immunei is a start-up that is hoping to change that by leveraging the exponential improvements

...